BidaskClub upgraded shares of Codexis (NASDAQ:CDXS) from a sell rating to a hold rating in a research report released on Saturday.

Other equities research analysts also recently issued reports about the stock. HC Wainwright set a $8.00 price objective on shares of Codexis and gave the stock a buy rating in a research report on Friday, August 11th. Zacks Investment Research downgraded shares of Codexis from a buy rating to a hold rating in a research report on Monday, August 14th. Jefferies Group upped their price objective on shares of Codexis from $9.00 to $11.00 and gave the stock a buy rating in a research report on Friday, October 13th. Finally, ValuEngine raised shares of Codexis from a sell rating to a hold rating in a research report on Friday, September 1st. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Codexis presently has a consensus rating of Hold and an average target price of $7.50.

Shares of Codexis (CDXS) opened at $6.60 on Friday. Codexis has a 52-week low of $3.60 and a 52-week high of $7.95.

In other news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $5.78, for a total transaction of $6,126,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 9.80% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Nationwide Fund Advisors lifted its stake in shares of Codexis by 15.7% during the 2nd quarter. Nationwide Fund Advisors now owns 21,568 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 2,928 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Codexis by 2.9% during the 1st quarter. Bank of America Corp DE now owns 25,477 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 717 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Codexis by 30.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 35,264 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 8,244 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Codexis by 23.3% during the 2nd quarter. Rhumbline Advisers now owns 42,872 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 8,095 shares in the last quarter. Finally, White Pine Capital LLC purchased a new stake in shares of Codexis during the 2nd quarter valued at approximately $277,000. Institutional investors own 65.71% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://theolympiareport.com/2017/12/06/codexis-cdxs-lifted-to-hold-at-bidaskclub.html.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.